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a  b  s  t  r  a  c  t
Enteropathogenic  Escherichia  coli  (EPEC)  is an important  cause  of diarrhea  in children.  EPEC adheres  to  the
intestinal  epithelium  and causes  attaching  and  effacing  (A/E)  lesions.  Recombinant  Mycobacterium  smeg-
matis  (Smeg)  and  Mycobacterium  bovis  BCG  strains  were  constructed  to express  either BfpA  or  intimin.
The  entire  bfpA  gene  and  a portion  of  the  intimin  gene  were  ampliﬁed  by  PCR  from  EPEC genomic  DNA
and  inserted  into  the  pMIP12  vector  at the  BamHI/KpnI  sites.  The  pMIP  bfpA  and  pMIP  intimin  vectors
were  introduced  separately  into  Smeg  and  BCG.  Recombinant  clones  were  selected  based  on  kanamycin
resistance  and designated  rSmeg  pMIP  (bfpA  or intimin)  and  rBCG  pMIP  (bfpA  or intimin).  The  expres-
sion  of  bfpA  and  intimin  was  detected  by  Immunoblotting  using  polyclonal  anti-BfpA  and  anti-intimin
antibodies.  The  immunogenicity  of  these  proteins  was  assessed  in C57BL/6  mice by  assaying  the  feces.  smegmatis
ecombinant vaccine
fpA  and intimin
and  serum  for the  presence  of  anti-BfpA  and anti-intimin  IgA  and  IgG antibodies.  TNF-  and  INF-  were
produced  in  vitro  by spleen  cells  from  mice  immunized  with  recombinant  BfpA,  whereas  TNF-  was  pro-
duced  in  mice  immunized  with  recombinant  intimin.  The  adhesion  of EPEC  (E2348/69)  to  HEp-2 target
cells  was  blocked  by IgA  or IgG antibodies  from  mice  immunized  with  recombinant  BfpA  or  intimin  but
not  by  antibodies  from  non-immunized  mice.  Immunogenic  non-infectious  vectors  containing  relevant
y  be  pEPEC  virulence  genes  ma
. Introduction
Diarrhea remains one of the top causes of death in low- and
iddle-income countries, in children under 5 years of age. A
ide range can be responsible for this illness. Enteropathogenic
scherichia coli (EPEC) strains are among the main bacterial causes
f this disease [1,2]. EPEC adheres to the host cells and induces
ttaching and effacing (A/E) lesions, culminating with induction
f diarrhea [3]. The formation of A/E lesions involves a type III
ecretion system encoded on pathogenicity island locus of ente-
ocyte effacement (LEE), which is responsible for delivering several
athogenic factors into host cells [4].
∗ Corresponding author at: Av. Vital Brazil, 1500, Sao Paulo, SP 05503-900, Brazil.
el.: +55 11 3726 7222x2001; fax: +55 11 3726 1505.
E-mail address: wds@butantan.gov.br (W.  Dias da Silva).
264-410X © 2012 Elsevier Ltd.
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Open access under the Elsevier OA license.romising  vaccine  candidates.
© 2012 Elsevier Ltd. 
Intimin is a 94–97 kDa protein expressed on the EPEC surface
that mediates adhesion of EPEC to the epithelial gut cells [4] that
mediates intimate contact with the bacterial translocated intimin
receptor (Tir) [5]. The N-terminal region is conserved among the
different intimin subtypes, while the C-terminal regions are highly
variable. The 29 intimin subtypes are identiﬁed according to their
C-terminal amino acid sequences [6–8]. Intimin- is the most com-
mon subtype expressed in EPEC isolates [9–11].
Bundle-forming pilus (BfpA) is another virulence factor, which
mediates the initial contact between EPEC and the host cell [12].
BfpA is encoded by a gene localized on a plasmid 50–70 MDa  in
size and is designated as EPEC adherence factor (EAF) [3,13–15].
Within adherent micro-colonies of EPEC, BfpA organizes a mesh-
work that allows bacteria to attach to each other and to tether
Open access under the Elsevier OA license.themselves to the host cell surface [3]. Therefore, BfpA and intimin
are two  important virulence factors and are considered to be
strategic target candidates for the design of a new vaccine against
EPEC.
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The generation of stable vectors expressing the desired
mmunogens is the goal of modern vaccine technology. The inclu-
ion of genes encoding relevant epitopes into living, non-infective
ectors that constitutively express immunological adjuvant com-
onents would be ideal. Attenuated bacteria have been used as
ectors to express and deliver heterologous antigens. This type of
accine vector is an attractive system because it can elicit mucosal,
umoral and cellular host immune responses to foreign antigens
16]. These live vectors have been used extensively to express anti-
ens of different types of pathogens, including viruses, bacteria
nd parasites, some of which have demonstrated positive results
17]. However, each vector has its unique features that should
e considered before it is used. In this study, the genes encoding
fpA and intimin were investigated using two different live vec-
ors: Mycobacterium bovis BCG Moreau (BCG) and Mycobacterium
megmatis mc2155 (Smeg) to generate the recombinant strains.
.  Materials and methods
.1.  Animals
C57BL/6 female mice, 4 weeks old, 18–22 g were supplied by Iso-
enic Mouse Breeding Facility of the Butantan Institute. All animals
ere cared under ethical conditions according to the Brazilian code
or the use of laboratory animals [18]. All protocols were approved
y the Animal Care and Ethics Committees at the Butantan Institute,
ão Paulo, Brazil.
.2.  Bacterial strains and growth conditions
All cloning steps were performed in DH5- E. coli strain
rown in Luria–Bertani broth (LB) supplemented with kanamycin
20 g/mL) or ampicillin (100 g/mL). Liquid cultures of BCG and
meg were grown in Middlebrook 7H9 media (MB7H9; Difco, MI,
SA) supplemented with oleic-albumin-dextrose-catalase (OADC)
MB7H9/OADC) with or without 20 g/mL kanamycin with gentle
haking at 37 ◦C. Eletrocompetent BCG and Smeg cells were pre-
ared and transformed by electroporation as previously described
19]. Transformed cultures were plated onto Middlebrook 7H10
gar plates supplemented with OADC (MB7H10/OADC) contain-
ng 20 g/mL kanamycin. The plates were incubated at 37 ◦C
or 3 weeks, and the transformants were expanded in liquid
B7H9/OADC media containing appropriate antibiotics.
.3.  Plasmid construction
The  bfpA and intimin (eae) genes were ampliﬁed by polymerase
hain reaction (PCR). The EPEC E2348/69 prototype genomic DNA
as used as a template, and the constructed oligonucleotide
rimers  were as follows: bfpA forward primer (FP) 5′-TAG GGA TCC
TG TCT TTG ATT GAA TCT GCA ATG GTG CTT-3′ and reverse primer
RP) 5′-TAG GGT ACC TTA CTT CAT AAA ATA TGT AAC TTT ATT
GT-3′; intimin FP 5′-TAG GGA TCC GGG ATC GAT TAC C-3′ and RP
′-TAG GGT ACC TTT ATC AGC CTT AAT CTC A-3′. The underlined
egions indicate KpnI and BamHI sites. Brieﬂy, the ampliﬁed BfpA
nd intimin (eae) PCR products were puriﬁed and sub-cloned into
he pGEM-T Easy vector (Promega, USA). Both genes were digested
ith BamHI and Kpnl and sub-cloned into the mycobacterial vec-
or pMIP12 (kindly provided by Brigitte Gicquel, Pasteur Institute,
rance). The resulting plasmids were identiﬁed as pMH12-bfpA and
MH12-intimin. The plasmids were validated by successive analy-
es with restriction endonucleases and DNA sequencing using the
rimer 5′-TTC AAA CTA TCG CCG GCT GA-3′.ne 30 (2012) 5999– 6005
2.4. Detection of BfpA and intimin in recombinant BCG and Smeg
by  immunoblotting
Whole-cell protein extracts of the recombinant BCG and Smeg
strains were resolved by SDS-PAGE (15%) and subsequently
transferred onto a nitrocellulose membrane. After the transfer,
nitrocellulose sheets were probed with mouse anti-BfpA or anti-
intimin polyclonal sera followed by anti-mouse IgG conjugated
with horseradish peroxidase as the secondary antibody. Puriﬁed
BfpA (19.5 kDa) and intimin (34 kDa) were used as positive con-
trols. The membranes were developed with a chemiluminescent
kit (MilliPore, USA) and were exposed on an Image Quant LAS 4000
(GE, USA).
2.5.  Mice immunization
Recombinant bacterial strains and their respective controls
(empty BCG or Smeg) were grown for 2 weeks until the late station-
ary phase (O.D.600 nm = 1.0), collected by centrifugation (2000 × g
at 4 ◦C for 10 min), washed twice and resuspended in PBS. Mice
were immunized on days 0, 15, 30 and 45 with 108 CFU in 200 L
PBS by oral gavage or by intraperitoneal injection. Control groups
received 200 L PBS or empty BCG and Smeg. Pre-immune sera and
feces were collected and analyzed for the presence of anti-BfpA and
anti-intimin antibodies prior to immunization.
2.6. Adjuvants
Recombinant BCG or Smeg expressing BfpA or intimin were
mixed with nanostructured silica adjuvant (SBA-15) according to
a previously described method [20]. SBA-15 silica was  kindly pro-
vided by Osvaldo Augusto SantıˇAnna, Butantan Institute, Brazil.
2.7.  Measurement of antibodies by ELISA
Fifteen days after the ﬁnal immunization, blood and feces were
collected. Blood was collected by retro-orbital bleeding and incu-
bated overnight at 4 ◦C before centrifuged at 1000 × g for 10 min
at room temperature and sera was transferred to new tubes and
stored at −20 ◦C. Feces were collected, weighed and re-suspended
in PBS containing 1 mM  phenylmethylsulphonyl ﬂuoride (PMSF)
(Boehringer Mannheim Co., USA) and 1% Bovine Serum Albumin
(BSA) (Fisher Scientiﬁc Co., USA) at a ratio of 1 g feces per 5 mL
inhibitory solution. After 15 min  on ice, the samples were shaken
and then centrifuged at 22,000 × g for 10 min, and the supernatants
were stored at −80 ◦C until use. Total immunoglobulin G (IgG) and A
(IgA) isotypes and the IgG1 or IgG2a antibody subclasses speciﬁc for
BfpA and intimin were evaluated by ELISA. Brieﬂy, microtiter plates
were coated overnight at 4 ◦C with 5 g/mL recombinant BfpA or
intimin (puriﬁed in our laboratory) in 100 L PBS. The plates were
then blocked with 10% BSA in PBS for 1 h at room temperature. After
each incubation, the plates were washed three times with PBS con-
taining 0.05% Tween-20 (PBST). Aliquots of serum and fecal extracts
were added to individual wells (100 L), and the plates were incu-
bated for 1 h at room temperature. After washing, the plates were
incubated with 100 L peroxidase-conjugated goat anti-mouse IgG
or anti-mouse IgA or anti-mouse IgG1 and IgG2a (Southern Biotech-
nologies, USA) at a dilution of 1:1000 in the same diluent pursued
by 1 h incubation at room temperature. The peroxidase activity was
measured using the o-phenylenediamine (OPD) substrate and read
at a wavelength of 450 nm.2.8. Detection of cytokines in spleen cell cultures
Spleens were recovered from immunized mice (5 animals per
group) 15 days after the ﬁnal immunization. Cell suspensions were
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Fig. 1. Expression of BfpA by recombinant Smeg and BCG vaccine strains. (A) Whole
extracts (30 g) of recombinant bacteria strains were resolved on SDS-PAGE and
BfpA protein identiﬁed by Immunoblotting using speciﬁc polyclonal mouse IgG
antibody as the ﬁrst antibody. Lane 1, MW;  Lane 2, puriﬁed BfpA; Lane 3, native
Smeg;  Lane 4, Smeg-BfpA; Lane 5, native BCG; and Lane 6, BCG-BfpA. (B) Expression
of  intimin by recombinant Smeg and BCG vaccine strains. Whole extracts (30 g)
of recombinant bacteria strains were resolved on SDS-PAGE and intimin proteinH.L.F. Vasconcellos et al. /
repared at a concentration of 5 × 106 cells/mL in RPMI medium
Gibco, USA) containing polymixin (1 g/mL) and were plated in
4-well plates. Cells were left unstimulated or were stimulated for
8 h with extracts of Smeg, BCG, puriﬁed BfpA, puriﬁed intimin or
onA (Sigma, USA) at a concentration of 5 g/mL at 37 ◦C in 5%
O2. Cytokine secretion was evaluated using the Cytometric Bead
rray Th1/Th2 Kit (CBA; BD Bioscience, USA) and samples were
ead on a FACS Calibur ﬂow cytometer (BD Biosciences, USA). Each
xperiment was repeated three times.
.9. Inhibition of EPEC adherence to Hep-2 cells
To evaluate the ability of the anti-recombinant BfpA and intimin
ntibodies to interfere with the adhesion of EPEC to host cells, a
tandard assay using HEp-2 target cells was used. Hep-2 cells were
aintained in DMEM supplemented with 10% SFB in a humidiﬁed
tmosphere containing 5% CO2 at 37 ◦C. To evaluate the inhibitory
ction of the speciﬁc antibodies, serum or fecal samples were incu-
ated at a ratio of 1:4 with 107 EPEC bacteria for 1 h at 37 ◦C before
eing added to the Hep-2 cultures. After the incorporation of the
acteria, the HEp-2 monolayers were kept at 37 ◦C for 3 h. The
Ep-2 monolayers were washed with PBS, ﬁxed with methanol
nd stained with Giemsa solution to visualize the adherent bacte-
ia by light microscopy. The percentage of HEp-2 cells with bound
acteria was determined for each tested antibody.
.10. Statistical analysis
Student’s  t-test was employed to determine the signiﬁcance of
ifferences between the studied groups. p values <0.05 (*) were
onsidered to be signiﬁcant.
.  Results
.1. Expression of BfpA and intimin by BCG and Smeg
DNA fragments encoding bfpA (600 bp) and intimin (eae388–667)
840 bp), were ampliﬁed by PCR from EPEC (E2348/69) and ligated
nto the KpnI and BamHI sites of the pMIP12 vector under the con-
rol of the pblaF* promoter (Supplementary Figure); the constructs
ere named pMH12-bfpA and pMH12-intimin, respectively. The
lasmids were electroporated into BCG and Smeg, and the resulting
trains were examined for BfpA and intimin expression. Expression
f both bfpA and intimin (eae) was conﬁrmed by immunoblotting
acterial whole-cell extracts using anti-BfpA or anti-intimin antis-
ra. As observed in Fig. 1A and B, the antisera speciﬁcally recognized
ands of approximately 19.5 and 34 kDa, corresponding to BfpA and
ntimin, respectively, from both rBCG and rSmeg strains. No pro-
eins were recognized by the antisera in whole-cell lysates from
CG or Smeg controls without the plasmid vectors (Fig. 1A and B).
.2.  Induction of antibodies by immunizing mice with
ecombinant BCG and Smeg
C57BL/6  mice were immunized by oral gavage or intraperi-
oneal injection with 4 doses of 1 × 108 CFU in 200 L of rBCG-bfpA,
Smeg-bfpA, rBCG-intimin or rSmeg-intimin at two-week intervals.
s a mucosal adjuvant, SBA-15 silica was used. Control mice were
mmunized with non-recombinant BCG or Smeg or with PBS follow-
ng the same immunization schedule. A signiﬁcantly higher level of
nti-BfpA and anti-intimin IgA or IgG antibodies was observed in
oth the feces and serum of mice immunized with rBCG or rSmeg as
ompared with that of serum collected in the groups that received
on-recombinant BCG or Smeg or PBS (p < 0.001) (Fig. 2A and B).
re-immune sera and feces that were collected and pooled wereidentiﬁed  by Immunoblotting using speciﬁc polyclonal mouse IgG antibody as the
ﬁrst antibody. Lane 1, MW;  Lane 2, puriﬁed intimin; Lane 3, native Smeg; Lane 4,
Smeg-intimin; Lane 5, native BCG; and Lane 6, BCG-intimin.
evaluated, and presented no reactivity to BfpA or intimin (data
not shown), suggesting the absence of anti-BfpA or anti-intimin
antibodies prior to immunization. Our analysis of serum IgG sub-
class responses also revealed that mice subjected to intraperitoneal
immunization predominantly developed an IgG2a response, indi-
cating a Th1-type cell response (Fig. 2C).
3.3. Development of a prevailing Th1-type cell response pattern
To  evaluate the involvement of Th1-type cells on the immune
responses induced by recombinant BCG-bfpA, BCG-intimin, Smeg-
bfpA and Smeg-intimin, spleen cells were recovered 15 days after
the ﬁnal immunization and treated in vitro with the corresponding
recombinant protein expressed in the vaccine used. We  assayed
the supernatants for the presence of the cytokines TNF-, IFN-,
IL-4 and IL-5. As is shown in Fig. 2A–C, anti-BfpA and anti-intimin,
respectively, IgA and IgG antibodies were detected in feces and
serum. Immunization with recombinant vaccine expressing BfpA
induced higher production of IFN-, in vitro, by spleen cells (Fig. 3).
The vaccination of mice with recombinant BCG or Smeg expressing
intimin induced higher levels of TNF- and IFN- production, in
vitro, by spleen cells (Fig. 4).
3.4. Immunization with recombinant BCG and Smeg induces
antibodies that inhibit EPEC (E2348/69) binding to Hep-2 cells
in  vitro
EPEC samples (E2348/69) pre-treated for 3 h with dilutions
of serum or fecal extracts obtained from mice immunized with
BCG-bfpA, BCG-intimin, Smeg-bfpA or Smeg-intimin, were added to
HEp-2 monolayers cultivated on coverslips. As a negative control,
EPEC (E2348/69) samples were similarly pre-treated with dilutions
of serum or feces collected prior to the immunizations. After incu-
◦bation for 3 h at 37 C, the coverslips were stained and examined
by light microscopy. Untreated EPEC (E2348/69) typically displays
a localized pattern of adhesion, generating tight microcolonies
of bacteria on the epithelial cell surface. As shown in Fig. 5A–C,
6002 H.L.F.  Vasconcellos et al. / Vaccine 30 (2012) 5999– 6005
Fig. 2. Detection of serum and feces antibodies IgA before and after oral immunization. (A) Serum (A) and feces (B) from immunized mice with four p.o. doses containing
108 CFU/200 L of Smeg-BfpA or BCG-BfpA or control group (PBS, native Smeg and native BCG) with SBA-15 adjuvant were collected on days 0 and 60 and the speciﬁc IgA
antibody anti-BfpA was analyzed by ELISA. (B) Detection of serum and feces antibodies IgA before and after oral immunization. Serum (A) and feces (B) from immunizaded
mice with four p.o. doses containing 108 CFU/200 L of Smeg-intimin or BCG-intimin or control group (PBS, native Smeg and native BCG) with SBA-15 adjuvant, were
collected on days 0 and 60 and the speciﬁc IgA antibody anti-intimin was analyzed by ELISA. (C) Detection of serum total speciﬁc antibodies IgG and isotypes IgG1 and IgG2a
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ith  recombinant vaccine Smeg-BfpA or Smeg-intimin (1 × 108 ufc/200 L) or BCG
meg  or BCG was  used as negative controls. t-Student ***p < 0.001.
dherence of EPEC (E2348/69) cells pre-treated with dilutions
f immune serum or fecal extracts was blocked by over 90%. In
ontrast, in EPEC (E2348/69) cells pre-treated with dilutions of
erum or feces collected before immunization, adherence was
locked by less than 5%.
.  Discussion
Attenuated M.  bovis BCG vaccine strains have been intensively
nvestigated as a vehicle for delivering heterologous antigens and
llowing the induction of both humoral (mucosal and systemic) and
ell-mediated immune responses [21].
In this study, we used recombinant BCG that expressed BfpA or
ntimin as vaccines against EPEC. As an alternative, M. smegmatis
as also used to present the BfpA and intimin antigens to the host.
t is interesting to note that the recombinant strains of both species
ere able to induce systemic and mucosal BfpA and intimin-
peciﬁc antibody responses with adherence-neutralizing activity
ollowing oral administration to mice. This evidence demonstrates
hat the different rBCG-EPEC or Smeg-EPEC vaccine strains areBfpA and anti-intimin were determined by ELISA from mice immunized four times
 or BCG-intimin (1 × 108 ufc/200 L) without SBA-15. Mice immunized with PBS or
potential  live vectors for the generation of strategies to prevent
EPEC.
Three important qualities for a recombinant vaccine were pos-
itively evaluated in our study. First, a live attenuated vaccine was
constructed with the ability to express two important proteins,
BfpA and intimin, involved in the pathogenesis of EPEC. Second,
the expression of the recombinant proteins induced speciﬁc and
long lasting immune response in immunized mice, characterized
by serum and mucosal IgG and IgA antibodies. The third impor-
tant property of our recombinants is that the induced antibodies
were able to prevent, in in vitro EPEC adherence to HEp-2 cells.
IgA production was  probably enhanced by the adjuvant effects of
mesoporous silica SBA-15 [20].
SBA-15 is a nontoxic positive modulator of the mucosal immune
response even in low immune responsive mice and is a natural
candidate to be included as an adjuvant in an anti-EPEC vaccine.
The anti-EPEC antibodies speciﬁcally recognize recombinant and
native BfpA and intimin proteins free in solution and naturally
ﬁxed on the bacterial cell surfaces (Fig. 1A and B). The signiﬁ-
cant production of TNF- and IFN- identiﬁes BfpA and intimin as
H.L.F. Vasconcellos et al. / Vaccine 30 (2012) 5999– 6005 6003
Fig. 3. Detection of cytokine production after in vitro stimulation of spleen cells from mice orally immunized with recombinant vaccines expressing recombinant BfpA.
Antigen speciﬁc production of TNF- (A); IFN- (B); IL-4 (C); and IL-5 (D) by spleen cells from mice immunized by the oral route with Smeg-BfpA or BCG-BfpA, was  measured
after stimulus with total extract soluble proteins of Smeg or BCG (25 g/mL); puriﬁed recombinant protein BfpA (25 g/mL) and ConA (5 g/mL), as positive control. Presented
results are representative of 3 independent experiments.
Fig. 4. Detection of cytokines production after stimulation of spleen cells in vitro from mice orally immunized with recombinant vaccines expressing protein intimin. Antigen
speciﬁc production of TNF- (A); IFN- (B); IL-4 (C); and IL-5 (D) by spleen cells from mice immunized by the oral route with Smeg-intimin or BCG-intimin, was measured
after stimulus with total extract soluble proteins of Smeg or BCG (25 g/mL); puriﬁed recombinant protein intimin (25 g/mL) and ConA (5 g/mL), as positive control.
Presented results are representative of 3 independent experiments.
6004 H.L.F.  Vasconcellos et al. / Vaccine 30 (2012) 5999– 6005
Fig. 5. Inhibition of binding properties of virulence factors BfpA and intimin by serum and feces samples collected from mice 15 days after last orally immunization. The
EPEC  E2348/69 strain was  incubated with different serum or feces samples for 1 h at 37 ◦C, at a ﬁnal dilution of 1:4 with 107 EPEC, before being added to HEp-2 cell cultures.
The inhibition of bacterial binding was evaluated by assays using feces (A1) or serum pools (B1 and C1) from PBS immunized mice, feces (A2) or serum (B2 and C2) pools
from mice orally immunized with Smeg, feces (A3) or serum (B3 and C3) pools from mice orally immunized with Smeg-bfpA, feces (A4) or serum pools from mice orally
immunized Smeg-intimin (B4 and C4), Hep-2 cells culture (A5, B5 and C5), feces (A6) or serum (B6 and C6) pools from mice orally immunized with BCG, feces (A7) or serum
(B7  and C7) pools from mice orally immunized with BCG-bfpA, and feces (A8) or serum (B8 and C8) pools from mice orally immunized with BCG-intimin. The results are
representative of three independent experiments with the same observed results.
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nducers of cellular immunity [22,23]. Although TNF participates
n the immune destruction of several infectious microbes [22], TNF
as ﬁrst identiﬁed in the plasma of LPS-treated animals exhibiting
he Shwartzman reaction [23]. The positive and negative effects of
NF must be taken into account when its production is induced by
andidates for protective vaccines. Although in vitro assays cannot
ntirely be used as substitutes for in vivo methods, the effective and
peciﬁc blockage of bacterial attachment to HEp-2 cells strongly
ndicates that the antibodies induced by the recombinant Smeg and
CG generated to express BfpA and/or intimin may  be active in vivo.
In a previous study, we demonstrated that an IgY antibody raised
gainst recombinant BfpA identiﬁes E. coli that express BfpA, blocks
olonization of HeLa cells by EPEC-EAF(+) in vitro and inhibits the
n vitro growth of EPEC-EAF(+) but not of EPEC-EAF(−) (the BfpA-
ured counterpart bacteria) [24]. More recently, we  also showed
hat EPEC-EAF(+)-expressing BfpA, but not EPEC-EAF(−), induced
poptosis in HeLa cells. This effect was blocked by prior neutraliza-
ion of BfpA with an IgY anti-BFP antibody [25]. These data agree
ith previous observations indicating that induction of epithelial
ell death by E. coli depends on the expression of bundle-forming
ili by the bacterium [26]. Therefore, BfpA is an important vir-
lence factor expressed by EPEC and is signiﬁcantly involved in
acterial cell adhesion and induction of host cell death, either by
ecrosis or apoptosis. Intimin is a 94–97 kDa outer membrane pro-
ein [4] that mediates intimate contact between the bacteria and
he target cell upon interaction with its translocated intimin recep-
or (Tir) [27]. Recent observations indicate that Lactobacillus casei
xpressing intimin- fragments and containing the immunodomi-
ant epitopes of Int280 induced both humoral and cellular immune
esponses in mice. The antibodies were able to bind to EPEC and
nhibit bacterial adhesion to the epithelial cell surface in vitro.
57BL/6 mice immunized with this recombinant strain became
artially protected against intestinal colonization by Citrobacter
odention, a mouse intestinal pathogen that also expresses intimin-
 [28]. BfpA and intimin are therefore signiﬁcant immunogens to
e used in vaccines.
cknowledgments
We  would like to thank the following individuals: Dr. Luciana
.C. Leite, Butantan Institute, São Paulo, Brazil, for her assistance
nd permission to use the Laboratory of Biotechnology IV; Dr.
rigitte Gicquel, Institute Pasteur, Paris, France, for providing the
MIP12 vector; Dr. Albert Schriefer, Fiocruz Institute, Salvador,
razil, for providing the original enteropathogenic E. coli (EPEC)-
AF(+) and -EAF(−) strains; and Dr. Dunia Rodriguez for expert
aboratory help and assistance in our results. “SBA-15 silica” was
indly provided by Osvaldo Augusto SantıˇAnna, Butantan Institute,
razil.
This work was supported by grants from the following: CNPq, for
he fellowship to the post-graduate student Halyka Luzório Fran-
otti Vasconcellos; FAPERJ, “Programa–Cientistas de Nosso Estado”,
roc. No.: E–26/100.628/200; CNPq: Bolsa de Produtividade (WDS)
ível 1A, Proc. No.: 301836/2005-1, FAPESP Proc. No.: 09/52804-0
nd BZG.
Conﬂict of interest statement: The authors have no ﬁnancial con-
ict of interest. This research is under the scope of the International
atents WO  07030901, IN248654, ZA2008/02277, KR 1089400 and
X297263.
ppendix A. Supplementary dataSupplementary data associated with this article can be
ound, in the online version, at http://dx.doi.org/10.1016/
.vaccine.2012.05.083.
[ne 30 (2012) 5999– 6005 6005
References
[1] Clark S, Haigh R, Freestone P, Williams P. Virulence of enteropathogenic
Escherichia  coli, a global pathogen. Clin Microbiol Rev 2003:365–78.
[2] Alrifai SB, Alsaadi A, Mahmood YA, Ali AA, Al-Kaisi LA. Prevalence and etiol-
ogy of nosocomial diarrhea in children 5 years in Tikrit teaching hospital. East
Mediterr Health J 2009;15:111–8.
[3] Donnenberg MS,  Giron JA, Nataro JP, Kaper JB. A plasmid-encoded type IV
ﬁmbrial gene of enteropathogenic Escherichia coli associated with localized
adherence. Mol  Microbiol 1992;6:3427–37.
[4] Jerse AE, Yu J, Tall BD, Kaper JB. A genetic locus of enteropathogenic
Escherichia  coli necessary for the production of attaching and effacing lesions
on tissue culture cells. Proc Natl Acad Sci U S A 1990;87:7839–43.
[5] Kenny B. Phosphorylation of tyrosine 474 of the enteropathogenic
Escherichia  coli (EPEC) Tir receptor molecule is essential for actin nucle-
ating activity and is preceded by additional host modiﬁcations. Mol  Microbiol
1999;31:1229–41.
[6] Fitzhenry R, Pickard D, Hartland EL, Reece S, Dougan G, Phillips AD. Intimin type
inﬂuences the site of human intestinal mucosal colonisation by enterohaem-
orrhagic Escherichia coli O157:H7. Gut 2002;50:80–5.
[7] Ito K, Lida M, Yamazaki M,  Moriya K, Moroishi S, Yatsuyanagi J, et al. Intimin
types determined by heteroduplex mobility assay 433 of intimin gene (eae)-
positive Escherichia coli strains. J Clin Microbiol 2007;45:1038–41.
[8] Mora A, Blanco M,  Yamamoto D, Dahbi G, Blanco JE, López C. HeLa-cell adher-
ence patterns and actin aggregation of enteropathogenic Escherichia coli (EPEC)
and Shiga-toxin-producing E. coli (STEC) strains carrying different eae and tir
alleles. Int Microbiol 2009;12:243–51.
[9] Aidar-Ugrinovich L, Blanco J, Blanco M, Blanco JE, Leomil L, Dahbi G, et al.
Serotypes, virulence genes, and intimin types of Shiga toxin-producing
Escherichia  coli (STEC) and enteropathogenic E. coli (EPEC) isolated from calves
in Sao Paulo, Brazil. Int J Food Microbiol 2007;115:297–306.
10]  Oswald E, Schmidt H, Morabito S, Karch H, Marches O, Caprioli A. Typing of
intimin genes in human and animal enterohemorrhagic and enteropathogenic
Escherichia coli: characterization of a new intimin variant. Infect Immun
2000;68:64–71.
11]  Ramachandran V, Brett K, Hornitzky MA,  Dowton M,  Bettelheim KA, Walker
MJ, et al. Distribution of intimin subtypes among Escherichia coli isolates from
ruminant and human sources. J Clin Microbiol 2003;41:5022–32.
12] Girón JA, Ho AS, Schoolnik GK. An inducible bundle forming pilus of
enteropathogenic Escherichia coli. Science 1991;254:710–3.
13]  Baldini MM,  Kaper JB, Levine MM,  Candy DC, Moon HW.  Plasmid-mediated
adhesion in enteropathogenic Escherichia coli. J Pediatr Gastroenterol Nutr
1983;2:534–8.
14]  Stone KD, Zhang HZ, Carlson LK, Donnenberg MS.  A cluster of fourteen genes
from enteropathogenic Escherichia coli is sufﬁcient for the biogenesis of a type
IV pilus. Mol  Microbiol 1996;20:325–37.
15] Sohel IJ, Puente L, Ramer SW,  Bieber D, Wu  C-Y, Scoolnik GK. Enteropathogenic
Escherichia coli: identiﬁcation of a gene cluster coding for bundle-forming pilus
morphogenesis. J Bacteriol 1996;178:2613–28.
16] Aldovini A, Young RA. Humoral and cell-mediated immune responses to live
recombinant BCG-HIV vaccines. Nature 1991;351:479–82.
17]  Ohara N, Yamada T. Recombinant BCG vaccines. Vaccine 2001;19:4089–98.
18] Giles TR. História da Educac¸ ão. São Paulo: EPU; 1987.
19] Parish T, Stoker NG. Electroporation of mycobacteria. Methods Mol Biol
1995;47:237–52.
20]  Carvalho LV, Ruiz RC, Scaramuzzi K, Marengo EB, Matos JR, Tambourgi DV,
et al. Anna OA. Immunological parameters related to the adjuvant effect of
the ordered mesoporous silica SBA-15. Vaccine 2010;28:7829–36.
21]  Nascimento IP, Dias WO,  Mazzantini RP, Miyaji EN, Gamberini M, Quintilio
Gebara VC, et al. Recombinant Mycobacterium bovis BCG expressing pertussis
toxin subunit S1 induces protection against an intracerebral challenge with live
Bordetella pertussis in mice. Infect Immun 2000;68:4877–83.
22]  Long KZ, Rosado JL, Santos JI, Haas M,  Mamum  AA, DuPont HL, et al. Associations
between mucosal innate and adaptive immune responses and resolution of
diarrheal pathogen infections. Infect Immun 2010;78:1221–8.
23] Harendra de Silva DG, Mendis LN, Sheron N, Alexander GJM, Candy DCA, Chart
H, et al. Concentrations of interleukin 6 and tumour necrosis factor in serum
and stools of children with Shigella dysenteriae infection. Gut  1993;34:194–8.
24] Almeida CMC, Quintana-Flores VM,  Medina-Acosta E, Schriefer A, Barral-Netto
M, Dias da Silva W.  Egg yolk anti-BfpA antibodies as a tool for recognizing and
identify enteropathogenic Escherichia coli. Scand J Immunol 2003;57:573–82.
25] Melo AR, Lasunskaia EB, Almeida CMC, Schriefer A, Kipnis TL, Dias da Silva W.
Expression of the virulence factor, BfpA, by enteropathogenic Escherichia coli
is essential for apoptosis signaling but not for NF-B activation in host cells.
Scand J Immunol 2005;61:511–610.
26] Khursigara C, Abul-Milh M,  Lau B, Giron JA, Lingwood CA, Foster DEB.
Enteropathogenic Escherichia coli virulence factor bundle-forming pilus
has a binding speciﬁcity for phosphatidylethanolamine. Infect Immun
2001;69:6573–9.
27]  Kenny B, Abe A, Stein M,  Finlay BB. Enteropathogenic Escherichia coli protein
secretion is induced in response to conditions similar to those in the gastroin-
testinal tract. Infect Immun 1997;65:2606–12.
28] Ferreira PCD, da Silva JB, Piazza RMF, Eckmann L, Ho PL, Oliveira MLS. Immu-
nization of mice with Lactobacillus casei expressing a beta-intimin fragment
reduces intestinal colonization by Citrobacter rodentium. Clin Vaccine Immunol
2011;18:1823–33.
